Proactive Therapeutic Drug Monitoring of Adalimumab Is Associated With Better Long-term Outcomes Compared With Standard of Care in Patients With Inflammatory Bowel Disease
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Proactive Therapeutic Drug Monitoring of Adalimumab Is Associated With Better Long-term Outcomes Compared With Standard of Care in Patients With Inflammatory Bowel Disease
Authors
Keywords
-
Journal
Journal of Crohns & Colitis
Volume -, Issue -, Pages -
Publisher
Oxford University Press (OUP)
Online
2019-01-20
DOI
10.1093/ecco-jcc/jjz018
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Prospective Observational Evaluation of Time-Dependency of Adalimumab Immunogenicity and Drug Concentrations: The POETIC Study
- (2018) Bella Ungar et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Clinical and Pharmacokinetic Factors Associated With Adalimumab-Induced Mucosal Healing in Patients With Crohn’s Disease
- (2018) Kenji Watanabe et al. Clinical Gastroenterology and Hepatology
- Maintenance Adalimumab Concentrations Are Associated with Biochemical, Endoscopic, and Histologic Remission in Inflammatory Bowel Disease
- (2018) Anna Juncadella et al. DIGESTIVE DISEASES AND SCIENCES
- Therapeutic Drug Monitoring Guides the Management of Crohn’s Patients with Secondary Loss of Response to Adalimumab
- (2018) Sophie Restellini et al. INFLAMMATORY BOWEL DISEASES
- OP031 Clinical effectiveness, safety and immunogenicity of anti-TNF therapy in Crohn’s disease: 12-month data from the PANTS study
- (2018) N A Kennedy et al. Journal of Crohns & Colitis
- Therapeutic Drug Monitoring is More Cost-Effective than a Clinically Based Approach in the Management of Loss of Response to Infliximab in Inflammatory Bowel Disease: An Observational Multicentre Study
- (2018) Luisa Guidi et al. Journal of Crohns & Colitis
- Proactive Infliximab Monitoring Following Reactive Testing is Associated With Better Clinical Outcomes Than Reactive Testing Alone in Patients With Inflammatory Bowel Disease
- (2018) Konstantinos Papamichael et al. Journal of Crohns & Colitis
- Influence of early adalimumab serum levels on immunogenicity and long-term outcome of anti-TNF naive Crohn's disease patients: the usefulness of rapid testing
- (2018) Bram Verstockt et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel Disease
- (2017) Joseph D. Feuerstein et al. GASTROENTEROLOGY
- Optimizing Anti-TNF-α Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases
- (2016) Bella Ungar et al. Clinical Gastroenterology and Hepatology
- Appropriateness of Testing for Anti–Tumor Necrosis Factor Agent and Antibody Concentrations, and Interpretation of Results
- (2016) Gil Y. Melmed et al. Clinical Gastroenterology and Hepatology
- Higher Adalimumab Levels Are Associated with Histologic and Endoscopic Remission in Patients with Crohnʼs Disease and Ulcerative Colitis
- (2016) Andres J. Yarur et al. INFLAMMATORY BOWEL DISEASES
- Post-Induction Adalimumab Concentration is Associated with Short-Term Mucosal Healing in Patients with Ulcerative Colitis
- (2016) Konstantinos Papamichael et al. Journal of Crohns & Colitis
- Higher Adalimumab Drug Levels are Associated with Mucosal Healing in Patients with Crohn’s Disease
- (2016) E. Zittan et al. Journal of Crohns & Colitis
- Association between serum adalimumab concentrations and endoscopic disease activity in patients with Crohn's disease
- (2016) Yukihiro Morita et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Prediction of clinical and endoscopic responses to anti-tumor necrosis factor-α antibodies in ulcerative colitis
- (2016) Yukihiro Morita et al. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
- Levels of Drug and Antidrug Antibodies Are Associated With Outcome of Interventions After Loss of Response to Infliximab or Adalimumab
- (2015) Henit Yanai et al. Clinical Gastroenterology and Hepatology
- Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease
- (2015) Niels Vande Casteele et al. GASTROENTEROLOGY
- Development of an Algorithm Incorporating Pharmacokinetics of Adalimumab in Inflammatory Bowel Diseases
- (2014) Xavier Roblin et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Association Between Serum Concentration of Infliximab and Efficacy in Adult Patients With Ulcerative Colitis
- (2014) Omoniyi J. Adedokun et al. GASTROENTEROLOGY
- Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial
- (2014) Freddy Cornillie et al. GUT
- Proactive Therapeutic Concentration Monitoring of Infliximab May Improve Outcomes for Patients with Inflammatory Bowel Disease
- (2014) Byron P. Vaughn et al. INFLAMMATORY BOWEL DISEASES
- A Test-based Strategy Is More Cost Effective Than Empiric Dose Escalation for Patients With Crohn's Disease Who Lose Responsiveness to Infliximab
- (2013) Fernando S. Velayos et al. Clinical Gastroenterology and Hepatology
- Comparative Effectiveness of Infliximab and Adalimumab for Crohn's Disease
- (2013) Mark T. Osterman et al. Clinical Gastroenterology and Hepatology
- Association Between Pharmacokinetics of Adalimumab and Mucosal Healing in Patients With Inflammatory Bowel Diseases
- (2013) Xavier Roblin et al. Clinical Gastroenterology and Hepatology
- Review article: loss of response to anti-TNF treatments in Crohn’s disease
- (2011) S. Ben-Horin et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started